About YCANTH (formerly VP-102)
YCANTH is a proprietary drug-device combination
product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted
administration for the treatment of molluscum. YCANTH is the only product approved by the FDA to treat molluscum a common, highly contagious skin disease that affects an
estimated six million people in the United States, primarily children. Please visit YCANTHPro.com for additional information.
In addition, Verrica has
successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts.
YCANTH should only be administered by a trained healthcare professional. YCANTH is not for home use.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, Verricas
lead product, YCANTH (cantharidin), became the first treatment approved by the FDA to treat pediatric and adult patients with molluscum contagiosum, a highly contagious viral skin infection
affecting approximately 6 million people in the United States, primarily children. VP-102 is also in development to treat common warts and external genital warts, two of the largest unmet needs in medical
dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to
develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for dermatologic
oncology conditions. For more information, visit www.verrica.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as believe, expect, may, plan, potential, will, and similar expressions, and
are based on Verricas current beliefs and expectations. These forward-looking statements include expectations regarding the continuing commercial launch of YCANTH, future financial performance, including expectations related to revenue and
inventory for the remainder of 2023 and the first half of 2024, and the potential benefits of potential benefits of YCANTH and Verricas product candidates to patients. These statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process,
Verricas reliance on third parties over which it may not always have full control and uncertainties that are described in Verricas Annual Report on Form 10-K for the year ended December 31,
2022, Verricas Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements
speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a
result of new information, future events or otherwise.